Melanotan II Side Effects: What Case Reports Reveal

Melanotan and Melanocortin

6x overdose

A 39-year-old man injected 6 mg of Melanotan II, six times the recommended starting dose. He was admitted to the ICU with rhabdomyolysis, a CPK of 17,773 IU/L, and acute kidney injury.

Nelson et al., Clinical Toxicology, 2012

Nelson et al., Clinical Toxicology, 2012

View as image

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that was originally developed at the University of Arizona in the 1990s. It activates melanocortin receptors MC1R through MC5R, which is why its effects extend far beyond skin tanning to include sexual arousal, appetite suppression, and cardiovascular changes.^[1] It has never been approved for any medical indication in any country. Despite this, it is widely available on the gray market and used for cosmetic tanning, often purchased from unregulated internet sources. The melanoma risk question is covered in our pillar article. This article catalogs every documented side effect from the clinical and case report literature.

Nausea: the universal acute side effect

Nausea was the first side effect identified in Melanotan II research and remains the most consistently reported. In the original Phase I clinical study by Dorr and colleagues, three healthy male volunteers received escalating subcutaneous doses of Melanotan II from 0.01 to 0.03 mg/kg.^[2] Mild nausea was reported at most dose levels. At the highest dose (0.03 mg/kg), one of two subjects also experienced Grade II somnolence and fatigue.

In the Wessells 1998 double-blind, placebo-controlled crossover study of Melanotan II for erectile dysfunction, 10 men received subcutaneous injections at 0.025 mg/kg.^[3] Nausea, stretching, yawning, and decreased appetite were reported more frequently after Melanotan II injections than placebo. None of these effects required treatment, and they were transient, typically resolving within hours.

The nausea appears dose-dependent. Users who begin at lower doses and titrate gradually report less nausea than those who start at higher doses. The mechanism likely involves MC4R activation in the area postrema and nucleus tractus solitarius, brainstem regions that regulate nausea and emesis. This is the same receptor pathway responsible for the appetite suppression effect.

Other acute symptoms reported alongside nausea include facial flushing (a vasomotor response to melanocortin receptor activation), yawning, fatigue, and decreased appetite. These are generally self-limiting and diminish with repeated use, suggesting partial tachyphylaxis develops at the receptor level.

Skin and mole changes: the dermatological concern

The intended effect of Melanotan II is increased skin pigmentation. It achieves this through MC1R activation on melanocytes, stimulating melanogenesis. The problem: melanocyte activation does not discriminate between normal skin and pre-existing melanocytic lesions.

The Habbema 2017 review in the International Journal of Dermatology compiled the dermatological complications reported across the literature.^[1] The findings include darkening of existing moles, rapid appearance of new nevi (including dysplastic nevi), and changes in the size and shape of pre-existing melanocytic lesions. These changes are clinically significant because dysplastic nevi are precursors to melanoma.

Four published case reports describe melanomas emerging from existing moles either during or shortly after melanotan use.^[1] Hjuler and colleagues documented a case where Melanotan II use was temporally associated with melanoma development in a patient who also used tanning beds.^[4] Ong and colleagues reported a melanoma in situ specifically associated with melanotan use.^[5]

Most recently, Yassin and colleagues in 2025 described a 22-year-old woman who developed oral mucosal malignant melanoma of the anterior maxilla after using Melanotan II nasal spray.^[6] This is a rare melanoma subtype, and the nasal route of administration meant Melanotan II had direct contact with oral and nasal mucosa, potentially providing localized melanocyte stimulation in addition to systemic effects.

Causation has not been proven. Melanoma develops through complex interactions between genetic susceptibility, UV exposure, and melanocyte biology. Users of Melanotan II are also disproportionately likely to use tanning beds, introducing a confounding variable. But the temporal associations, the known pharmacology (melanocyte activation), and the biological plausibility have led multiple national health organizations to issue warnings.

Cardiovascular effects: blood pressure, heart rate, and renal infarction

Melanotan II activates MC4R in the central nervous system, which increases sympathetic nervous system outflow. This translates to measurable cardiovascular effects in humans.

In the Nelson 2012 case report, a 39-year-old man injected 6 mg of Melanotan II subcutaneously (approximately 6 times the typical starting dose).^[7] Within 2 hours, he presented with blood pressure of 151/85 mmHg, a heart rate of 130 bpm that peaked at 146 bpm, mydriasis (dilated pupils), diaphoresis (sweating), and diffuse muscle tremors. The clinical picture resembled sympathomimetic toxicity. His creatine phosphokinase (CPK) rose from 1,760 IU/L at admission to 17,773 IU/L 12 hours later, confirming rhabdomyolysis. Troponin was elevated at 0.23 ng/mL, indicating cardiac stress. Creatinine was 2.25 mg/dL, reflecting acute kidney injury. He required 3 days in the ICU.

The Peters 2020 case report documented a longer-term cardiovascular consequence.^[8] A man who had administered 27 mg of Melanotan II over 6 months developed right-sided renal infarction, with CT revealing approximately 50% of the kidney affected. He had been previously normotensive but his blood pressure was recorded at 165/95 mmHg. The mechanism may involve chronic sympathetic activation, pro-thrombotic effects, or direct vascular toxicity. This was the first reported case of Melanotan II-associated renal infarction.

The melanocortin blood pressure connection explains why MC4R activation raises blood pressure through central sympathetic outflow. This is not unique to Melanotan II. The FDA-approved MC4R agonist setmelanotide also carries a blood pressure monitoring requirement in its prescribing information.

Rhabdomyolysis and systemic toxicity

The Nelson 2012 case^[7] represents the most severe documented acute toxicity from Melanotan II. The key details:

• CPK peaked at 17,773 IU/L (normal range is 22-198 IU/L for males)
• Creatinine reached 2.25 mg/dL (normal is 0.7-1.3 mg/dL)
• Troponin was 0.23 ng/mL (elevated above normal, suggesting cardiac muscle involvement)
• White blood cell count was 19.1 k/microL (elevated, indicating stress response)
• Urinalysis showed 3+ blood with red cell casts but minimal actual red blood cells, classic for myoglobin in the urine from muscle breakdown

The patient received benzodiazepines for agitation and intravenous fluids with sodium bicarbonate for rhabdomyolysis. His CPK decreased to 2,622 IU/L and creatinine improved to 1.23 mg/dL upon ICU discharge after 3 days. Mass spectrometry confirmed the injected substance was Melanotan II.

The dose was approximately 6 mg, far exceeding the 0.5-1 mg doses typically discussed in user communities. But the substance was purchased online, and users have no reliable way to verify concentration or purity. Dosing errors with unregulated peptides are a recognized pattern across the gray market.

Sexual side effects: erections, priapism, and arousal

Melanotan II's effects on sexual function were recognized early in clinical development. The Wessells 1998 study demonstrated that subcutaneous Melanotan II at 0.025 mg/kg produced erections in men with psychogenic erectile dysfunction at rates significantly higher than placebo in a double-blind crossover design.^[3]

This effect occurs through MC4R and MC3R activation in the hypothalamus and spinal cord, triggering central nervous system-mediated erectile pathways. It is the same mechanism that led to the development of bremelanotide (Vyleesi), a closely related melanocortin peptide that received FDA approval for hypoactive sexual desire disorder in premenopausal women.

Priapism (a prolonged, painful erection lasting more than 4 hours and requiring emergency treatment) has been reported with Melanotan II use. This represents a genuine medical emergency because sustained priapism can cause ischemic damage to penile tissue. The Dorr 1996 Phase I study noted spontaneous erections as a side effect, and the progression from unwanted erections to priapism at higher doses or in susceptible individuals is pharmacologically predictable.^[2]

The connection between melanocortin pathways, pigmentation, and sexual arousal explains why a tanning peptide produces sexual side effects: MC4R regulates both processes.

Product quality and contamination risks

A side effect category specific to unregulated peptides is the risk from the product itself rather than the active compound. Melanotan II purchased from internet sources is manufactured without regulatory oversight, quality control, or good manufacturing practice (GMP) standards.

The Habbema 2017 review highlighted this concern: questions exist regarding the preparation, administration, and dosage of these substances.^[1] Reported issues with gray market melanotan include: incorrect or variable concentration of active ingredient, presence of contaminants (bacterial endotoxins, heavy metals, residual solvents), degradation products from improper storage or shipping, and the possibility of receiving a completely different compound.

Users typically reconstitute lyophilized powder with bacteriostatic water and self-inject subcutaneously, introducing additional risks from non-sterile technique. Injection site infections, abscess formation, and the transmission of blood-borne pathogens from shared needles or contaminated supplies have all been reported in the broader context of injectable peptide use.

How Melanotan II compares to the approved melanocortin drug

Afamelanotide (Scenesse) is a closely related alpha-MSH analog that received regulatory approval for erythropoietic protoporphyria (EPP), a rare photosensitivity disorder. Unlike Melanotan II, afamelanotide has been through formal clinical trials with long-term safety monitoring. The Habbema review noted that "although afamelanotide has been thoroughly tested and deemed safe, illegal melanotans are likely risky for several reasons."^[1]

Afamelanotide is a linear peptide (Melanotan I), not a cyclic peptide like Melanotan II. It has higher selectivity for MC1R and lower activity at MC3R, MC4R, and MC5R. This narrower receptor profile means fewer off-target effects: less sexual arousal, less blood pressure elevation, and less appetite suppression. The safety difference between the two compounds is partly molecular (receptor selectivity) and partly regulatory (quality control, dosing precision, monitoring).

The Bottom Line

Melanotan II's side effect profile ranges from predictable and mild (nausea, flushing, appetite suppression) to rare and severe (rhabdomyolysis, renal infarction, melanoma). The acute effects are driven by non-selective melanocortin receptor activation across MC1R through MC5R. The severe outcomes have been documented exclusively in case reports from unregulated use, where dosing errors and product quality are uncontrolled variables. No formal Phase 2 or Phase 3 safety trial has ever been completed, so the true incidence of serious adverse events is unknown. What exists is a growing collection of case reports from dermatologists, toxicologists, and emergency physicians encountering the consequences of widespread unregulated use.

Frequently Asked Questions

What are the most common side effects of melanotan II?

The most frequently reported side effects are nausea, facial flushing, decreased appetite, fatigue, and yawning. In the only Phase I clinical trial, nausea occurred at every dose level tested. These acute effects are generally transient, resolving within hours of injection, and appear to diminish with repeated use.

Can melanotan II cause melanoma?

Four published case reports describe melanomas emerging from existing moles during or shortly after melanotan use. A 2025 case documented oral mucosal melanoma after nasal spray use. Causation has not been proven because users often also use tanning beds, but the biological mechanism (melanocyte stimulation) makes the association plausible. Multiple national health agencies have issued warnings.

Does melanotan II affect blood pressure?

Yes. Melanotan II activates MC4R in the brain, which increases sympathetic nervous system activity and raises blood pressure. A case report documented a previously normotensive man developing hypertension (165/95 mmHg) after 6 months of use. In an acute overdose case, blood pressure reached 151/85 with heart rate peaking at 146 bpm.

Is melanotan II legal?

Melanotan II is not approved for any medical use in any country. Regulatory agencies in the US, UK, Australia, and multiple European countries have issued warnings against its use. It remains available through unregulated internet sources, typically sold as a "research chemical." Possession for personal use occupies a legal gray area that varies by jurisdiction.

Can melanotan II cause kidney damage?

Case reports document two mechanisms of kidney injury. In one case, a man developed rhabdomyolysis (CPK 17,773 IU/L) with acute kidney injury after a single high-dose injection. In another, a man developed renal infarction (50% of one kidney) after 6 months of use, potentially from chronic hypertension or pro-thrombotic effects.

What happens if you take too much melanotan II?

Acute overdose has been documented in case reports. A 39-year-old man who injected 6 mg (approximately 6 times the starting dose) developed sympathomimetic toxicity: tachycardia (146 bpm), hypertension, mydriasis, sweating, muscle tremors, and rhabdomyolysis requiring 3 days of ICU care. Because the product is unregulated, dosing errors are a recognized risk.